ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
Open accessThe DOI matches its Crossref record; 143 of the 143 references it cites were found in a registry or an index.
Abstract
Advanced Breast Cancer (ABC) is a treatable but still generally incurable disease. The goals of care are to optimize both length and quality of life. Due to continuous research, several advances have been made, particularly for the HER-2-positive and for Luminal-like subtypes. Notwithstanding these advances, median overall survival of patients with ABC is still only 2e3 years, although the range is wide, and survival may be longer for patients treated in specialized institutions. Implementation of current knowledge is highly variable among countries and within each country. The use of treatment guidelines has been associated with a significant improvement in survival. This has been achieved mainly in early breast cancer. For ABC, and particularly metastatic breast cancer (MBC), less level 1 evidence exists and only recently have international consensus guidelines been developed (ABC1 e). The ABC Consensus Conference was created by the European School of Oncology (ESO) with the ambitious goal of improving outcomes for all patients with advanced breast cancer. Backed by strong political advocacy, ABC guidelines are seeking to improve standards of care, to raise awareness about how to best meet to the needs of this underserved group of patients, and to identify research priorities so that clinical research is focused on the most important areas of unmet need. Following the work of the ESO-ABC Task Force, created in 2005, and the successful undertaking of the 1st International Consensus Guidelines Conference on ABC (ABC1), held in November 2011, the 2nd International Consensus Conference for Advanced Breast Cancer (ABC2) took place in Lisbon, Portugal, on
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 1×
“For HER-2-positive LABC, anthracyclines should not be administered concurrently with trastuzumab since this approach does not increase the pCR rate, and it could increase the risk of cardiac toxicity, based largely on studies in the metastatic setting [35,36].”
BackgroundSelf-citationTrastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834 · cited 2×
“lapatinib plus capecitabine in the subset of 118 patients who were randomized in the first-line setting, having relapsed on or within 6 months of adjuvant trastuzumab, appeared similar to the effect seen in the overall trial [100].”
BackgroundResultSelf-citationEverolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863 · cited 1×
“The mTOR inhibitor everolimus when added to exemestane, in patients progressing on non-steroidal aromatase inhibitor, provided a significant PFS prolongation of about 5 months [89,90].”
BackgroundSelf-citationPertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532 · cited 1×
“The CLEOPATRA trial [96,97]; showed superior results, in terms of PFS (18.”
ResultEarly palliative care for patients with advanced cancer: a cluster-randomised controlled trial
Zimmermann, C., Swami, N., Krzyzanowska, M., Hannon, B., Leighl, N., Oza, A., Moore, M., Rydall, A., Rodin, G., Tannock, I., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62416-2 · Cited by 1,781 · cited 1×
“The multidisciplinary approach of ABC should encompass early in the history of the disease not only physical, but also functional, social, psychological, and spiritual, domains [25–27].”
BackgroundMiller, K. D., Chap, L. I., Holmes, F. A., Cobleigh, M. A., Marcom, P. K., Fehrenbacher, L., Dickler, M., Overmoyer, B. A., Reimann, J. D., Sing, A. P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.098 · Cited by 1,306 · cited 1×
“Capecitabine has shown consistent results as first- and second-line therapy [104–112].”
ResultSelf-citationGrading Strength of Recommendations and Quality of Evidence in Clinical Guidelines
Guyatt, G., Gutterman, D., Baumann, M. H., Addrizzo-Harris, D., Hylek, E. M., Phillips, B., Raskob, G., Lewis, S. Z., & Schünemann, H. (2006) · Chest · doi:10.1378/chest.129.1.174 · Cited by 1,220 · cited 1×
“Table 1 describes the grading system used [15].”
MethodCortes, J., O'Shaughnessy, J., Loesch, D., Blum, J. L., Vahdat, L. T., Petrakova, K., Chollet, P., Manikas, A., Diéras, V., Delozier, T., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60070-6 · Cited by 1,094 · cited 1×
“Eribulin has provided an OS benefit in heavily pretreated patients (up to 5 lines of treatment) [115] and similar PFS and OS results to capecitabine after prior treatment with an anthracycline and taxane [116].”
ResultSelf-citationRobert, N. J., Diéras, V., Glaspy, J., Brufsky, A. M., Bondarenko, I., Lipatov, O. N., Perez, E. A., Yardley, D. A., Chan, S. Y. T., Zhou, X., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.0982 · Cited by 1,064 · cited 1×
“Capecitabine has shown consistent results as first- and second-line therapy [104–112].”
Resultvon Minckwitz, G., Schneeweiss, A., Loibl, S., Salat, C., Denkert, C., Rezai, M., Blohmer, J. U., Jackisch, C., Paepke, S., Gerber, B., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70160-3 · Cited by 1,022
Research works printed but not linked: 2
- Handesman D Androgen Actions and Pharmacologic Uses, Endocrinology 2001 Philadelphia WB Saunders 2232 2242
- Wildiers H Kim SB Gonzalez-Martin A T-DM1 for HER2-positive metastatic breast cancer (MBC): primary results from TH3RESA, a phase 3 study of T-DM1 vs treatment of physician's choice 2013 Presented at the European Cancer Congress September 27–October 1 Amsterdam, The Netherlands (abstr LBA15)
Cited by
Items 101–200 of 540
Qin, X., Guo, X., Liu, T., Li, L., Zhou, N., Ma, X., Meng, X., Liu, J., Zhu, H., Jia, B., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05967-7 · Cited by 55
International EANM-SNMMI-ISMRM consensus recommendation for PET/MRI in oncology
Veit‐Haibach, P., Ahlström, H. K., Boellaard, R., Bolton, R. C. D., Hesse, S., Hope, T. A., Huellner, M. W., Iagaru, A. H., Johnson, G. B., Kjær, A., et al. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06406-x · Cited by 54
“Several studies have shown, for example, that even in small pulmonary nodules, the lung parenchyma and mediastinal and pleural infiltration can be evaluated with advanced PET/ MRI techniques (gating, UTE/ZTE, motion correction, radial Fourier plane acquisitions) [61, 107–112].”
BackgroundTwelves, C., Awada, A. H., Cortés, J., Yelle, L., Velikova, G., Olivo, M. S., Song, J., Dutcus, C. E., & Kaufman, P. A. (2016) · Breast Cancer Basic and Clinical Research · doi:10.4137/bcbcr.s39615 · Cited by 53
Park, I. H., Im, S., Jung, K. H., Sohn, J., Park, Y. H., Lee, K. S., Sim, S. H., Park, K. H., Kim, J. H., Nam, B., et al. (2018) · Cancer Research and Treatment · doi:10.4143/crt.2017.562 · Cited by 50
Wilson, F. R., Varu, A., Mitra, D., Cameron, C. G., & Iyer, S. S. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4404-4 · Cited by 50
Janni, W., Alba, E., Bachelot, T., Diab, S., Gil‐Gil, M., Beck, T., Ryvo, L., López‐López, R., Tsai, M. L., Esteva, F. J., et al. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4658-x · Cited by 51
“Endocrine therapy (ET)-based regimens are the cornerstone of treatment in patients with HR+ , human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC) [3].”
BackgroundBrain, E. G. C., Caillet, P., de Glas, N. A., Biganzoli, L., Cheng, K. K. F., Lago, L. D., & Wildiers, H. P. M. W. (2019) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2019.06.004 · Cited by 53
Self-citationMarrufo, A. M., Mathew, S. O., Chaudhary, P., Malaer, J. D., Vishwanatha, J. K., & Mathew, P. A. (2018) · Europe PMC (PubMed Central) · Cited by 59
Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer
Başaran, G., Twelves, C. J., Dieras, V. C., Cortés, J., & Awada, A. H. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.12.002 · Cited by 51
Berger, F., Marce, M., Delaloge, S., Bessard, A. C. H., Bachelot, T., Bièche, I., Pradines, A., Rouge, T. D. L. M., Canon, J.-L. R., André, F., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-055821 · Cited by 57
Self-citationBakoyiannis, I., Tsigka, E.-A., Perrea, D. N., & Pergialiotis, V. (2015) · Clinical Drug Investigation · doi:10.1007/s40261-015-0364-9 · Cited by 47
“Its prevalence among breast cancer tumors is estimated to be approximately 70 % [1, 2].”
BackgroundLosurdo, A., Rota, S., Gullo, G., Masci, G., Torrisi, R., Bottai, G., Zuradelli, M., Gatzemeier, W., & Santoro, A. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.03.013 · Cited by 45
“Recent ESO-ESMO international consensus guidelines recommend that when an AI is to be used in advanced MaBC patients, a concomitant LHRH agonist or orchiectomy should be added to further down-regulate testicular function (Cardoso et al., 2014).”
BackgroundHormonoresistance in advanced breast cancer: a new revolution in endocrine therapy
Augereau, P., Patsouris, A., Bourbouloux, E., Gourmelon, C., Lacourtoisie, S. A., Rigaud, D. B., Soulié, P., Frenel, J., & Campone, M. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017693195 · Cited by 50
Brodowicz, T., Hadji, P., Niepel, D., & Diel, I. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.09.008 · Cited by 49
Isakoff, S. J., Puhalla, S., Domchek, S. M., Friedlander, M. L., Kaufman, B., Robson, M. E., Telli, M. L., Dieras, V. C., Han, H. S., Garber, J. E., et al. (2016) · Future Oncology · doi:10.2217/fon-2016-0412 · Cited by 48
Self-citationHealth-related quality of life in women with breast cancer: a review of measures
Salas, M., Mordin, M., Castro, C., Islam, Z., Tu, N., & Hackshaw, M. D. (2022) · BMC Cancer · doi:10.1186/s12885-021-09157-w · Cited by 67
Chaudhari, D., Kuche, K., Yadav, V., Ghadi, R., Date, T., Bhargavi, N., & Jain, S. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-022-01273-9 · Cited by 48
“There were trails conducted for evaluating targeted therapeutics against TNBC but majority of them showed insignificant improvement in therapy [5].”
BackgroundMeeting the needs of breast cancer: A nucleolin’s perspective
Gregório, A. C., Lacerda, M., Figueiredo, P., Simões, S., Dias, S., & Moreira, J. N. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.03.008 · Cited by 50
Sorafenib for the treatment of breast cancer
Bronte, G., Andreis, D., Bravaccini, S., Maltoni, R., Cecconetto, L., Schirone, A., Farolfi, A., Fedeli, A., Serra, P., Donati, C., et al. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1309024 · Cited by 48
“The main objective of systemic treatment is the improvement of survival and quality of life [7].”
BackgroundNoguchi, S., Kim, H. J., Anita, J., Parmar, V. V., Sato, N., Wang, H.-C., Lokejaroenlarb, S., Isidro, J., Kim, K. S., Itoh, Y., et al. (2015) · Breast Cancer · doi:10.1007/s12282-015-0637-4 · Cited by 43
“However, this combination therapy approach was in line with current clinical practice guidelines [10, 19].”
BackgroundResultTabouret-Viaud, C., Botsikas, D., Delattre, B. M. A., Mainta, I., Amzalag, G., Rager, O., Vinh‐Hung, V., Miralbell, R., & Ratib, O. M. (2015) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2015.03.003 · Cited by 43
Fulvestrant and male breast cancer: a pooled analysis
Zagouri, F., Sergentanis, T. Ν., Chrysikos, D., Dimopoulos, M. A., & Ψαλτοπούλου, Θ. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3240-z · Cited by 43
“Furthermore, this pooled analysis was confined to case reports and case series, a fact that might have introduced bias to our findings, given that these studies, according to the 2014 ESO-ESMO (ABC2) consensus guidelines [3, 4], correspond to level of evidence 2C (observational studies or case series).”
ResultJackisch, C., Lammers, P. E., & Jacobs, I. A. (2017) · The Breast · doi:10.1016/j.breast.2017.01.010 · Cited by 47
“Initial results from some trials show promising efficacy and safety for T-DM1 in combination with pertuzumab [88–90].”
InfluentialBrufsky, A. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.06.004 · Cited by 50
Fallowfield, L. J., Boyle, F. M., Travado, L., Kiely, B. E., Jewell, P., Aubel, D., & Cardoso, F. (2021) · JCO Global Oncology · doi:10.1200/go.21.00045 · Cited by 44
“The terms advanced, metastatic, secondary, and stage IV are frequently used interchangeably by HCPs, and across different countries, which can be confusing for patients.(6,7) Some information leaflets and resources available online suffer from the same problem.”
BackgroundSelf-citationJackisch, C., Müller, V., Dall, P., Neumeister, R., Park-Simon, T.-W., Ruf-Dördelmann, A., Seiler, S., Tesch, H., & Ataseven, B. (2015) · Geburtshilfe und Frauenheilkunde · doi:10.1055/s-0035-1546172 · Cited by 42
Rüschoff, J., Lebeau, A., Kreipe, H. H., Sinn, H., Gerharz, C. D., Koch, W., Morris, S., Ammann, J. U., & Untch, M. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.164 · Cited by 48
Montagna, E., Palazzo, A., Maisonneuve, P., Cancello, G., Iorfida, M., Sciandivasci, A., Espósito, A., Cardillo, A., Mazza, M., Munzone, E., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.01.027 · Cited by 42
Self-citationNabieva, N., & Fasching, P. A. (2021) · Cancers · doi:10.3390/cancers13225643 · Cited by 45
“This is why it was approved and recommended for the therapy of aBC, especially in the first or second treatment line [34,37,38].”
BackgroundPerez, E. A. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.11.001 · Cited by 43
Bleckmann, A., Conradi, L., Menck, K., Schmick, N. A., Schubert, A., Rietkötter, E., Arackal, J., Middel, P., Schambony, A., Liersch, T., et al. (2016) · Clinical & Experimental Metastasis · doi:10.1007/s10585-016-9780-3 · Cited by 45
“However, the overall survival decreases dramatically to only 2–3 years for patients on diagnosis of distant metastasis [2].”
Mutation matters in precision medicine: A future to believe in
Dey, N., Williams, C. B., Leyland-Jones, B. R., & De, P. K. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.03.002 · Cited by 44
Turković, L., Bočkor, L., Ekpenyong, O., Silovski, T., Lovrić, M., Crnković, S., Nigović, B., & Sertić, M. (2022) · Pharmaceuticals · doi:10.3390/ph15050614 · Cited by 44
Lousberg, L., Collignon, J., & Jérusalem, G. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016665077 · Cited by 43
Bychkovsky, B., & Lin, N. (2016) · The Breast · doi:10.1016/j.breast.2016.06.017 · Cited by 39
Reinert, T., & Barrios, C. H. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017728928 · Cited by 48
Self-citationLi, S., Zhao, J., Zhu, L., Su, F., & Chen, K. (2017) · Cancer Medicine · doi:10.1002/cam4.1224 · Cited by 39
Mortensen, G. L., Madsen, I. B., Krogsgaard, R., & Ejlertsen, B. (2017) · Acta Oncologica · doi:10.1080/0284186x.2017.1406141 · Cited by 47
“Palliation may also include bone modifying agents, pain medication, antidepressants or anti-emetics, for instance [7,10].”
BackgroundCurrent report of natural product development against breast cancer stem cells
Hermawan, A., & Putri, H. (2018) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2018.09.012 · Cited by 42
Chartron, E., Theillet, C. G., Guiu, S., & Jacot, W. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.10.012 · Cited by 45
Survival of de novo stage IV breast cancer patients over three decades
Hölzel, D., Eckel, R., Bauerfeind, I., Baier, B., Beck, T., Braun, M., Ettl, J., Hamann, U., Harbeck, N., Kiechle, M. B., et al. (2016) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-016-2306-1 · Cited by 38
“The value of removal seems to be unknown (Cardoso et al. 2014) despite the fact that greater than half of 15 retrospective studies achieved a significant improvement of survival following treatment (Criscitiello et al. 2015; Ruiterkamp et al. 2010).”
BackgroundSelf-citationAromatase inhibitors in male breast cancer: a pooled analysis
Zagouri, F., Sergentanis, T. Ν., Azim, H. A., Chrysikos, D., Dimopoulos, M. A., & Ψαλτοπούλου, Θ. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3356-9 · Cited by 39
“According to ESMO and NCCN guidelines, tamoxifen is the gold-standard adjuvant endocrine therapy in male breast cancer and plays an important role in the metastatic setting [3–5].”
BackgroundMethodGarrone, O., Montemurro, F., Saggia, C., Verde, N. M. L., Vandone, A. M., Airoldi, M., Conciliis, E. D., Donadio, M., Lucio, F., Polimeni, M. A., et al. (2016) · SpringerPlus · doi:10.1186/s40064-016-1700-0 · Cited by 38
Watson, G. A., Deac, O. M., Aslam, R., O’Dwyer, R., Tierney, A., Sukor, S., & Kennedy, J. (2018) · Clinical Breast Cancer · doi:10.1016/j.clbc.2018.09.002 · Cited by 38
Update on Precision Medicine in Breast Cancer
Sachdev, J. C., Sandoval, A. C., & Jahanzeb, M. (2019) · Cancer treatment and research · doi:10.1007/978-3-030-16391-4_2 · Cited by 39
Yardley, D. A., Brufsky, A., Coleman, R. E., Conte, P., Cortés, J., Glück, S., Nabholtz, J., O’Shaughnessy, J., Beck, R. M., Ko, A., et al. (2015) · Trials · doi:10.1186/s13063-015-1101-7 · Cited by 40
Self-citationKirchner, J., Grueneisen, J. S., Martin, O., Oehmigen, M., Quick, H. H., Bittner, A., Hoffmann, O., Ingenwerth, M., Catalano, O. A., Heusch, P., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4102-4 · Cited by 38
Thomssen, C., Lüftner, D., Untch, M., Haidinger, R., Würstlein, R., Harbeck, N., Augustin, D., Briest, S., Ettl, J., Fasching, P. A., et al. (2020) · Breast Care · doi:10.1159/000505957 · Cited by 38
Self-citationSurgery of the primary tumor in de novo metastatic breast cancer: To do or not to do?
Criscitiello, C., Giuliano, M., Curigliano, G., Laurentiis, M. D., Arpino, G., Carlomagno, N., Placido, S. D., Golshan, M. A., & Santangelo, M. L. (2015) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2015.07.013 · Cited by 39
Lindman, H., Wiklund, F. E., & Andersen, K. K. (2022) · BMC Cancer · doi:10.1186/s12885-022-10098-1 · Cited by 40
Metronomic chemotherapy for advanced breast cancer patients
Cazzaniga, M. E., Dionísio, M. R., & Riva, F. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.12.019 · Cited by 35
Walzer, S., Ponzetti, C., Canciani, M., Farina, M., & Era, S. (2016) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s97319 · Cited by 35
Andersson, M., López-Vega, J. M., Petit, T., Zamagni, C., Easton, V., Kamber, J., Restuccia, E., & Perez, E. A. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0079 · Cited by 33
Zhang, Y., Zeng, X., Deng, H., Ma, F., Ye, P., Yi, L., Tan, C., & Peng, L. (2019) · Clinical Therapeutics · doi:10.1016/j.clinthera.2019.04.033 · Cited by 42
HER2-positive metastatic breast cancer: A changing scenario
Mustacchi, G., Biganzoli, L., Pronzato, P., Montemurro, F., Dambrosio, M., Minelli, M., Molteni, L., & Scaltriti, L. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.02.002 · Cited by 39
Self-citationBulten, B. F., Verberne, H. J., Bellersen, L., Oyen, W. J. G., Sabaté-Llobera, A., Mavinkurve‐Groothuis, A. M. C., Kapusta, L., van Laarhoven, H. W. M., & de Geus‐Oei, L. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2874-9 · Cited by 35
“Anthracyclines are widely used for (neo)adjuvant treatment of breast cancer [11, 27].”
BackgroundMukai, H., Kato, K., Esaki, T., Ohsumi, S., Hozomi, Y., Matsubara, N., Hamaguchi, T., Matsumura, Y., Goda, R., Hirai, T., et al. (2016) · Investigational New Drugs · doi:10.1007/s10637-016-0381-4 · Cited by 37
“Although taxanes can be used as the first-line therapy, they have not shown superior benefits to anthracyclines [10].”
BackgroundSchmidt, M., Lenhard, H. G., Hoenig, A., Zimmerman, Y., Krijgh, J., Jansen, M., & Bennink, H. J. T. C. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03472-8 · Cited by 39
Skeletal metastases from breast cancer: pathogenesis of bone tropism and treatment strategy
Fontanella, C., Fanotto, V., Rihawi, K., Aprile, G., & Puglisi, F. (2015) · Clinical & Experimental Metastasis · doi:10.1007/s10585-015-9743-0 · Cited by 38
Discrepancies between ESMO and NCCN breast cancer guidelines: An appraisal
Zagouri, F., Liakou, P., Bartsch, R., Peccatori, F. A., Tsigginou, A., Dimitrakakis, C., Zografos, G., Dimopoulos, M. A., & Azim, H. A. (2015) · The Breast · doi:10.1016/j.breast.2015.02.031 · Cited by 36
Nakamura, N., Kawamori, J., Takahashi, O., Shikama, N., Sekiguchi, K., Takahashi, T., Kato, S., Ogita, M., Motegi, A., & Akimoto, T. (2018) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyy054 · Cited by 32
Radionuclide-Based Imaging of Breast Cancer: State of the Art
Li, H., Liu, Z., Yuan, L., Fan, K. S., Zhang, Y., Cai, W., & Lan, X. (2021) · Cancers · doi:10.3390/cancers13215459 · Cited by 35
“Immunohistochemistry staining is considered the ‘gold standard’ for assessing these receptors [155].”
BackgroundFerrero, J.-M., Bessard, A. C. H., Capitain, O., Lortholary, A. H., Salles, B., Follana, P., Hervé, R., Deblock, M., Dauba, J., Atlassi, M., et al. (2016) · Cancer · doi:10.1002/cncr.30170 · Cited by 33
Tamoxifen induces a pluripotency signature in breast cancer cells and human tumors
Notas, G., Pelekanou, V., Kampa, M., Alexakis, K., Sfakianakis, S. G., Laliotis, A., Askoxilakis, J., Tsentelierou, E., Tzardi, M. N., Tsapis, A., et al. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.05.008 · Cited by 37
“Although the issue of the time-point that defines primary and secondary endocrine resistance is still under debate (Cardoso et al., 2014; Harbeck et al., 2014), two out of the five patients studied, developed resistance to tamoxifen after more than two years suggesting partial tamoxifen…”
BackgroundLambertini, M., Ferreira, A. R., Meglio, A. D., Poggio, F. B., Puglisi, F., Sottotetti, F., Montemurro, F., Poletto, E., Bernardo, A., Risi, E., et al. (2017) · Clinical Breast Cancer · doi:10.1016/j.clbc.2017.04.002 · Cited by 33
“Introduction Metastatic breast cancer (MBC) is a treatable but still generally incurable disease, and the goals of care are to optimize length as well as quality of life.(1,2) In the past decades, several advances in the treatment of MBC patients have been made with improvement in their survival.”
Wood, R. P., Mitra, D., de Courcy, J. J., & Iyer, S. S. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.07.009 · Cited by 36
Over-treatment in metastatic breast cancer
Senkus, E., & Łacko, A. (2016) · The Breast · doi:10.1016/j.breast.2016.06.024 · Cited by 40
Self-citationSEOM clinical guidelines in metastatic breast cancer 2015
Gavilá, J., López‐Tarruella, S., Saura, C., Muñoz-Mateu, M., Oliveira, M., de la Cruz‐Merino, L., Morales, S. M., Álvarez, I., Virizuela, J. A., & Martín, M. (2015) · Clinical & Translational Oncology · doi:10.1007/s12094-015-1476-7 · Cited by 34
“In general, sequencing single-agent chemotherapy is preferred [27], limiting combination therapies for patients with aggressive, symptomatic or life-threatening disease [3] (level of certainty: high; strength of recommendation: A).”
BackgroundInfluentialKourié, H. R., Chaix, M., Gombos, A., Aftimos, P., & Awada, A. H. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2016.1198317 · Cited by 36
“Current treatment guidelines recommend dual anti-HER2 blockade with pertuzumab plus trastuzumab plus a taxane as the preferred first-line regimen in metastatic HER2-positive breast cancer [29,30].”
Backgroundde Anda‐Jáuregui, G., Mejía-Pedroza, R. A., Enríquez, J. E., & Lemus, E. H. (2015) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2015.07.004 · Cited by 32
“Benefits related to tamoxifen adjuvant therapy include an increase in overall survival and distant disease-free survival, reduction of breast cancer-specific mortality, decreased risk of recurrence, and decreased risk of contralateral breast cancer (Cardoso et al., 2014).”
BackgroundPalumbo, R., Sottotetti, F., & Bernardo, A. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016639873 · Cited by 32
Thermal Skin Damage During Reirradiation and Hyperthermia Is Time-Temperature Dependent
Bakker, A., Kolff, M. W., Holman, R., van Leeuwen, C. M., Straten, L. K.-V., Oldenhof, R. D. K., Rasch, C. R. N., van Tienhoven, G., & Crezee, J. (2017) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2017.02.009 · Cited by 29
Does the 1H-NMR plasma metabolome reflect the host-tumor interactions in human breast cancer?
Richard, V., Conotte, R., Mayne, D., & Colet, J. (2017) · Oncotarget · doi:10.18632/oncotarget.18307 · Cited by 31
“However, despite progresses in therapies and supportive cares of advanced diseases, the majority of relapsing patients die of the malignancy or its complications [2].”
BackgroundMethodGenerali, D., Venturini, S., Rognoni, C., Ciani, O., Pusztai, L., Loi, S., Jérusalem, G., Bottini, A., & Tarricone, R. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3453-9 · Cited by 28
Matter-Walstra, K. W., Ruhstaller, T., Klingbiel, D., Schwenkglenks, M. M., & Dedes, K. J. (2016) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-3822-z · Cited by 31
“Endocrine therapy (ET) remains the optimal first-line treatment for ERHER2 disease in most cases [3, 4].”
Rocca, A., Farolfi, A., Maltoni, R., Carretta, E., Melegari, E., Ferrario, C., Cecconetto, L., Sarti, S., Schirone, A., Fedeli, A., et al. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3423-2 · Cited by 34
“Endocrine therapy is the first-line treatment of choice for patients with hormone receptor-positive advanced breast cancer (ABC), excluding those with important symptoms or life-threatening visceral involvement and rapidly progressive disease [1].”
BackgroundAftimos, P. G., Polastro, L., Ameye, L., Jungels, C., Vakili, J., Paesmans, M., van den Eerenbeemt, J., Buttice, A., Gombos, A., de Valeriola, D. L., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.03.010 · Cited by 28
Self-citationLebon, V., Alberini, J., Pierga, J., Dieras, V. C., Jehanno, N., & Wartski, M. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.178749 · Cited by 29
“Indeed, current international guidelines recommend the use of 18F-FDG PET/CT only for clinical stages III and IV, regardless of age (12); U.”
MethodDecker, T. W., Overkamp, F., Rösel, S., Nusch, A., Göhler, T., Indorf, M., Sahlmann, J., & Trarbach, T. (2017) · BMC Cancer · doi:10.1186/s12885-017-3492-1 · Cited by 29
“Although current guidelines recommend taxan-based chemotherapy early in the course of the disease [8], taxanes are often used in clinical practice in later treatment lines to avoid alopecia and long standing neuropathy (N.”
Real-world effectiveness of CDK 4/6 inhibitors in estrogen-positive metastatic breast cancer
Gehrchen, M. L., Berg, T., Garly, R., Jensen, M., Eßer-Naumann, S., Rønlev, J. D., Nielsen, H. M., Knoop, A. S., & Kümler, I. (2024) · BJC Reports · doi:10.1038/s44276-024-00070-w · Cited by 32
Migliaccio, I., Malorni, L., Hart, C. D., Guarducci, C., & Leo, A. D. (2015) · BMC Medicine · doi:10.1186/s12916-015-0280-0 · Cited by 31
Current and emerging therapies of HER2-positive metastatic breast cancer
Hernández-Blanquisett, A., Touya, D., Strasser‐Weippl, K., Ruiz, R., Louis, J. S., & Goss, P. E. (2016) · The Breast · doi:10.1016/j.breast.2016.07.026 · Cited by 31
Sbitti, Y., Slimani, K. A., Debbagh, A., Mokhlis, A., Kadiri, H., Laraqui, A., Errihani, H. H., & Ichou, M. (2017) · World Journal of Oncology · doi:10.14740/wjon1043w · Cited by 27
“In real-world practice, patients with visceral crisis are more likely to receive chemotherapy, often because their vital organs are affected [3].”
BackgroundHonkanen, T. J., Moilanen, T., Karihtala, P., Tiainen, S., Auvinen, P., Väyrynen, J. P., Mäkinen, M. J., & Koivunen, J. P. (2017) · Scientific Reports · doi:10.1038/s41598-017-18266-1 · Cited by 30
Komatsu, H., Yagasaki, K., Yamaguchi, T., Mori, A., Kawano, H., Minamoto, N., Honma, O., & Tamura, K. (2020) · European Journal of Oncology Nursing · doi:10.1016/j.ejon.2020.101780 · Cited by 31
Takashima, T., Tokunaga, S., Tei, S., Nishimura, S., Kawajiri, H., Kashiwagi, S., Yamagata, S., Noda, S., Nishimori, T., Mizuyama, Y., et al. (2016) · SpringerPlus · doi:10.1186/s40064-016-1833-1 · Cited by 26
“the case of immediately life-threatening disease (Partridge et al. 2014; Cardoso et al. 2014).”
Trédan, O., Follana, P., Moullet, I., Cropet, C., Träger-Maury, S., Dauba, J., Lavau‐Denès, S., Dieras, V. C., Beal-Ardisson, D., Gouttebel, M.-C., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw077 · Cited by 27
Endophytic fungi: A future prospect for breast cancer therapeutics and drug development
Varghese, S., Jisha, M. S., Rajeshkumar, K. C., Gajbhiye, V., Alrefaei, A. F., & Jeewon, R. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e33995 · Cited by 33
“To mitigate these inequalities, resource-sensitive [77] and resource-stratified guidelines [78,79] have been created to provide general models for interventions in low-resource settings.”
BackgroundLambertini, M., Ferreira, A. R., Poggio, F. B., Puglisi, F., Bernardo, A., Montemurro, F., Poletto, E., Pozzi, E., Rossi, V., Risi, E., et al. (2015) · The Oncologist · doi:10.1634/theoncologist.2015-0020 · Cited by 29
Watanabe, J. (2015) · SpringerPlus · doi:10.1186/s40064-015-1422-8 · Cited by 27
“…License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.”
BackgroundInfluentialDefining the optimal sequence for the systemic treatment of metastatic breast cancer
Albanell, J., iMolins, A. B., Martínez, L. C., López-Muñiz, J. I. C., Gil, E. M. C., Ferré, A. D. J., Barco, S. D., Pérez, Y. F., Mata, J. G., Palomo, A. G., et al. (2016) · Clinical & Translational Oncology · doi:10.1007/s12094-016-1520-2 · Cited by 26
Male Breast Cancer: A Single-Institution Clinicopathologic and Immunohistochemical Study
Serdy, K. M., Leone, J. P., Dabbs, D. J., & Bhargava, R. (2016) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqw207 · Cited by 29
Schwartzberg, L. S., & Vidal, G. A. (2020) · Clinical Breast Cancer · doi:10.1016/j.clbc.2020.02.002 · Cited by 28
Vrdoljak, E., Gligorov, J., Wierinck, L., Conte, P., Grève, J. D., Meunier, F., Palmieri, C., Travado, L., Walker, A., Wiseman, T., et al. (2020) · The Breast · doi:10.1016/j.breast.2020.12.005 · Cited by 31
“Although early BC is treatable and potentially curable, up to 10% of patients are diagnosed at an advanced stage in developed countries, and 20e30% of patients experience progression to metastatic BC (mBC), even if diagnosed early and appropriately managed [2,3].”
BackgroundSelf-citationThungappa, S. C., Maksud, T., Raut, N. V., Nagarkar, R. V., Batra, U., Mendiratta, S. K., & Parmar, D. (2021) · Clinical Breast Cancer · doi:10.1016/j.clbc.2021.11.006 · Cited by 26
Review on the clinical use of eribulin mesylate for the treatment of breast cancer
Aseyev, O., Ribeiro, J. M., & Cardoso, F. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1146683 · Cited by 26
“The chemical name for eribulin mesylate is: 11,15:18,21:24,28-Triepoxy-7,9-ethano-12,15-methano9H,15Hfuro[3,2-i]furo[2 ́,3 ́:5,6]pyrano [4,3- b][1,4] dioxacyclopentacosin-5(4H)-one, 2-[(2S)-3-amino-2 hydroxypropyl]hexacosahydro-3-methoxy-26-methyl20,27bis(methylene)-,(2R,3R,3aS,7R, 8aS,9S,10aR,11S,12R,13aR,13bS,15S,18…”
BackgroundInfluentialSelf-citationTherapeutic Implications of the Molecular and Immune Landscape of Triple-Negative Breast Cancer
Gregório, A. C., Lacerda, M., Figueiredo, P., Simões, S., Dias, S., & Moreira, J. N. (2017) · Pathology & Oncology Research · doi:10.1007/s12253-017-0307-2 · Cited by 28
Araki, K., Fukada, I., Yanagi, H., Kobayashi, K., Shibayama, T., Horii, R., Takahashi, S., Akiyama, F., Ohno, S., & Ito, Y. (2017) · The Breast · doi:10.1016/j.breast.2017.06.015 · Cited by 25
Ki67 and progesterone receptor status predicts sensitivity to palbociclib: a real-world study
Shao, X., Zheng, Y., Cao, W., Shen, X., Li, G., Chen, J., Huang, Y., Huang, P., Shi, L., Ye, W.-W., et al. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-1340 · Cited by 27
“Palbociclib was considered as first-line therapy (LOT1) if it was given in the setting of no prior systemic treatment for ABC or at least 1 year from the completion of adjuvant endocrine therapy.”
BackgroundInfluentialThe role of ctDNA detection and the potential of the liquid biopsy for breast cancer monitoring
Openshaw, M. R., Page, K., Fernández-García, D., Guttery, D. S., & Shaw, J. (2016) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2016.1184974 · Cited by 27
Metadata
- Authors
- Cardoso, F., Costa, A., Norton, L., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Biganzoli, L., Blackwell, K. L., Cardoso, M. J., Cufer, T., El Saghir, N., Fallowfield, L., Fenech, D., Francis, P., Gelmon, K., Giordano, S. H., Gligorov, J., Goldhirsch, A., Harbeck, N., Houssami, N., Hudis, C., Kaufman, B., Krop, I., Kyriakides, S., Lin, U. N., Mayer, M., Merjaver, S. D., Nordström, E. B., Pagani, O., Partridge, A., Penault-Llorca, F., Piccart, M. J., Rugo, H., Sledge, G., Thomssen, C., van't Veer, L., Vorobiof, D., Vrieling, C., West, N., Xu, B., & Winer, E.
- Affiliations
- Centro Champalimaud (PT)
- European School of Oncology (CH)
- Memorial Sloan Kettering Cancer Center (US)
- Gdańsk Medical University (PL)
- Clinique de Genolier (CH)
- Institut Gustave Roussy (FR)
- Pontifícia Universidade Católica do Rio Grande do Sul (BR)
- Karolinska University Hospital (SE)
- Fondazione Sandro Pitigliani (IT)
- Duke University (US)
- Champalimaud Foundation (PT)
- Brighton and Sussex Medical School (GB)
- Europa Donna (IT)
- Peter MacCallum Cancer Centre (AU)
- BC Cancer Agency (CA)
- The University of Texas MD Anderson Cancer Center (US)
- Université Pierre-et-Marie-Curie (FR)
- European Institute of Oncology (IT)
- Ludwig-Maximilians-Universität München (DE)
- The University of Sydney (AU)
- Sheba Medical Center (IL)
- Dana-Farber Cancer Institute (US)
- University of Michigan (US)
- Europa Donna (GE)
- Istituto Oncologico della Svizzera Italiana (CH)
- Centre Jean Perrin (FR)
- Institut Jules Bordet (BE)
- University of California, San Francisco (US)
- Indiana University (US)
- Martin Luther University Halle-Wittenberg (DE)
- Cardiff and Vale University Health Board (GB)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Corresponding author
- Cardoso, F.
- ORCID
- Cardoso, F.
- Costa, A.
- Norton, L.
- Senkus, E.
- Aapro, M.
- André, F.
- Barrios, C.H.
- Bergh, J.
- Biganzoli, L.
- Cardoso, M.J.
- Fallowfield, L.
- Francis, P.
- Gelmon, K.
- Giordano, S.H.
- Gligorov, J.
- Harbeck, N.
- Houssami, N.
- Hudis, C.
- Kaufman, B.
- Krop, I.
- Pagani, O.
- Partridge, A.
- Penault-Llorca, F.
- Piccart, M.J.
- Rugo, H.
- Sledge, G.
- Thomssen, C.
- Vorobiof, D.
- Vrieling, C.
- Xu, B.
- Winer, E.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2014-10
- Volume
- 25
- Issue
- 10
- Pages
- 1871-1888
- ISSN
- 0923-7534 (ISSN-L)
- PMC
- PMC4176456
- OpenAlex
- W2127287298
- Cited by
- 540
- References
- 143
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 15 · 2023: 23 · 2022: 20 · 2021: 24 · 2020: 38 · 2019: 37 · 2018: 57 · 2017: 107 · 2016: 124 · 2015: 84 · 2014: 2
- FWCI
- 33.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 1878 d)
- Locations
- Annals of Oncology (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-nd)
- Sussex Research Online (University of Sussex) (submittedVersion, cc-by-nc-nd)
- OAR@UM (University of Malta) (submittedVersion, other-oa)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion, other-oa)
- Figshare (submittedVersion, cc-by-nc-nd)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- advanced breast cancer, metastatic breast cancer, treatment guidelines, HER2-positive breast cancer, luminal breast cancer, overall survival, quality of life, standard of care, unmet medical needs, research priorities
- MeSH terms
- Breast Neoplasms, Female, Humans, Treatment Outcome, Guidelines as Topic, Neoplasm Grading
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.